10:38 AM EST - Theratechnologies Inc. : Today announced the availability of EGRIFTA WR™ (tesamorelin) for injection for the reduction of excess abdominal fat in adult patients with HIV and lipodystrophy. The announcement follows the approval of EGRIFTA WR™ by the U.S. Food and Drug Administration (FDA) earlier this year. Theratechnologies Inc.
shares T.TH are trading unchanged at $4.50.
